AI-generated analysis. Always verify with the original filing.
Alterity Therapeutics announced that CEO David Stamler, M.D., will participate in a fireside chat titled 'Optimising Late-stage Clinical Trials to Increase the Odds' and host 1-on-1 investor meetings at the Bell Potter Healthcare Horizons Summit on 12-13 March 2026 in Sorrento, Australia. This provides investors an opportunity to engage directly with leadership on the company's Phase 3 MSA trial preparations and ATH434 program.